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Abstract
Background
Studies looking at acquired drug resistance (ADR) are diverse with respect to geographical
distribution, HIV co-infection rates, retreatment status and programmatic factors such as
regimens administered and directly observed therapy. Our objective was to examine and
consolidate evidence from clinical studies of the multifactorial aetiology of acquired rifamy-
cin and/or isoniazid resistance within the scope of a single systematic review. This is impor-
tant to inform policy and identify key areas for further studies.
Methods
Case-control and cohort studies and randomised controlled trials that reported ADR as an
outcome during antitubercular treatment regimens including a rifamycin and examined the
association of at least 1 risk factor were included. Post hoc, we carried out random effects
Mantel-Haenszel weighted meta-analyses of the impact of 2 key risk factors 1) HIV and 2)
baseline drug resistance on the binary outcome of ADR. Heterogeneity was assessed used
I2 statistic. As a secondary outcome, we calculated median cumulative incidence of ADR,
weighted by the sample size of the studies.
Results
Meta-analysis of 15 studies showed increased risk of ADR with baseline mono- or polyresis-
tance (RR 4.85 95% CI 3.26 to 7.23, heterogeneity I2 58%, 95% CI 26 to 76%). Meta-analy-
sis of 8 studies showed that HIV co-infection was associated with increased risk of ADR
(RR 3.02, 95% CI 1.28 to 7.11); there was considerable heterogeneity amongst these stud-
ies (I2 81%, 95% CI 64 to 90%). Non-adherence, extrapulmonary/disseminated disease
and advanced immunosuppression in HIV co-infection were other risk factors noted. The
weighted median cumulative incidence of acquired multi drug resistance calculated in 24
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Conclusion
Baseline drug resistance and HIV co-infection were significant risk factors for ADR. There
was a trend of positive association with non-adherence which is likely to contribute to the
outcome of ADR. The multifactorial aetiology of ADR in a programmatic setting should be
further evaluated via appropriately designed studies.
Introduction
Resistance to both first line antitubercular drugs rifampicin (of the rifamycin drug class) and
isoniazid (multi drug resistant tuberculosis (MDR TB)) is an increasing global health problem.
The World Health Organisation (WHO) estimates there were 450,000 cases of MDR TB with
170,000 deaths in 2012 [1]. Cure and completion rates are lower than for drug susceptible TB,
with higher mortality rates [2] and there is huge cost to health systems. Whilst transmitted
drug resistance has been highlighted as important in fuelling the spread of the epidemic, a bet-
ter understanding of what factors contribute to the initial emergence of resistance is needed to
inform policy. Acquired drug resistance (ADR) is the development, fixation and amplification
of mutations conferring resistance under drug pressure during treatment. Verification of true
ADR requires ruling out initial dual mixed infection or subsequent exogenous re-infection
with a drug resistant strain ofM. tuberculosis (MTB).
ADR has been recognised since chemotherapy was first discovered. The early emergence of
ADR with streptomycin monotherapy, heralded the need for multidrug regimens to achieve
cure and prevent further accumulation of resistance. The inclusion of rifampicin and pyrazina-
mide in TB regimens since the 1970s led to shortening of TB regimens from 2 years to 6
months. The rate of stochastic acquired drug resistance has been calculated to be in the order
of 2.25 x 1010 mutations per bacterium per generation for rifampicin and 2.56 x 108 mutations
per bacterium per generation for isoniazid [3] within the human host. Upon the background of
this natural evolution of resistance, programmatic factors such as problems in maintaining
drug supplies and ensuring patient adherence and treatment completion have remained and
contributed to the global MDR epidemic through creating the selective pressure necessary for
ADR to emerge.
A recently published study of ADR in a hollow fibre model system has questioned the con-
ventional notion that poor adherence accounts for the majority of ADR [4]. Several plausible
explanations as to how HIV could predispose to ADR have been proposed including malab-
sorption of antitubercular drugs [5] and host immunosuppression leading to tolerance of
strain-specific polymorphisms in the pathway to drug resistance [6]. However, whether HIV is
indeed a risk factor for ADR remains to be clarified. The objective of this review was to consoli-
date evidence from studies that examined any risk factors for acquired rifamycin and/or isonia-
zid resistance in patients undergoing antitubercular therapy containing a rifamycin at least
during the intensive phase. After conducting the systematic review, a post-hoc decision was
taken to carry out 2 separate meta-analyses focused on: 1) HIV infection 2) baseline drug resis-
tance as risk factors for the binary outcome of ADR.
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Methods
We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA) guidelines. We registered the review in PROSPERO (crd.york.ac.uk
CRD42014003856).
Selection criteria
We included case-control and cohort studies and randomised controlled trials (RCTs) report-
ing ADR as either a primary or secondary adverse outcome. To be included, studies had to
examine the association of at least 1 risk factor with ADR. Also, patients of any age needed to
be on regimens of at least 6 months’ duration which contained rifamycin at least in the inten-
sive phase. We excluded studies that defined ADR as cases of baseline resistance in patients
undergoing retreatment for TB. Studies that reported no cases of ADR were excluded. We did
not limit our case definition of ADR to studies that had ruled out exogenous re-infection or ini-
tial dual mixed infection with different strains using genotypic methods. However, where the
data was available, we excluded cases identified as exogenous re-infection via genotyping.
Although we collected data on baseline drug sensitivities, the performance of drug sensitivity
testing (DST) at baseline in the entire cohort was not required for inclusion. This allowed for
inclusion of studies from settings where baseline DST was not routinely performed, but our
analyses focussed on those patients in the cohort who did have baseline DST. ADR was defined
as identification of new resistance (compared with a baseline isolate of known DST) to rifamy-
cin and/or isoniazid which was made after minimum of 2 weeks on TB treatment or after com-
pletion of TB treatment.
Search strategy
Searches were run in Pubmed/MEDLINE, EMBASE, Cochrane Library, Web of Science, Biosis
previews and the Trip Database from 1950 to January 2014. In Pubmed, filters were used to
select the following languages: Chinese; English; Italian; Russian; Spanish; French. Our key-
words were ‘tuberculosis’ or ‘Mycobacterium tuberculosis’ AND ‘acquired drug resistance’ OR
‘amplified drug resistance.’ We hand-searched reference lists of reviews and eligible papers for
other relevant articles in English.
Study selection, data extraction and quality assessment
Two reviewers (NR, GM) independently assessed the titles and abstracts of studies from the
searches based on pre-specified eligibility criteria. If it was unclear from the abstract whether
inclusion criteria were met, the full article was reviewed. Any uncertainty or disagreement
about eligibility was resolved through discussion.
The two reviewers then independently extracted data using a structured data extraction
form. Any disagreements were discussed. In cases of missing or incomplete information
authors were contacted. Critical appraisal tools, developed in the Critical Appraisal Skills Pro-
gramme (CASP) for judging methodological quality of RCTs, cohort and case control studies,
were amalgamated and used to judge methodological quality [7].
Data synthesis
Risk factors for ADR were tabulated for all studies. If univariate or multivariate analyses were
performed, then only if there was a significant association with ADR was the factor categorised
as ‘risk factor for ADR’. If no statistical analysis was performed but a risk factor for ADR was
described in the study, it was reported as per trend noted. Random effects meta-analyses with
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Mantel-Haenszel weighting were performed for the covariates baseline drug resistance and
HIV co-infection for the binary outcome of ADR using the Cochrane Collaboration Review
Manager Version 5.3 statistical software. We calculated risk ratios (RR) and their correspond-
ing 95% confidence intervals (CI) and p-values. Heterogeneity between studies was assessed by
calculating the I2 statistic and its corresponding 95% CI using Stata version 13.1. As a second-
ary outcome, the cumulative incidence of acquired isoniazid, rifamycin and MDR was reported
for individual studies. Patients with known baseline MDR were excluded from calculations.
When feasible, the incidence of ADR was calculated using the following denominators: 1) as a
proportion of the whole cohort, 2) as a proportion of those with follow up DST, 3) as a propor-
tion of those with baseline pan-susceptibility, 4) as a proportion of those with baseline monore-
sistance and 5) as a proportion of those with baseline polyresistance. The median cumulative
acquired isoniazid, acquired rifamycin and acquired MDR incidence across all studies that
reported these was also calculated, weighted by the overall sample size of each study.
Results
Study selection and assessment
We identified 798 citations through the electronic database searches: 703 were excluded after
abstract review. Another 26 studies were identified through reference review. One hundred full
text articles were examined and 32 deemed eligible (6 RCTs, 8 prospective cohort, 15 retrospec-
tive cohort and 3 case control studies) (Fig 1).
Table 1, S1 and S2 Tables provide detailed break down and aggregate data of studies
included in the review. Certain studies restricted inclusion to specific populations: those with
HIV co-infection (n = 5) [8–10], those incarcerated (n = 1) [11], those with silicotuberculosis
(n = 1) [12], those with isoniazid monoresistance (n = 1) [13] and retreatment patients (n = 2)
[14–15]. S3 Table provides an appraisal of study quality [7]. Loss to follow up was not noted to
be significant (pre-defined threshold 20%) in any study. We assessed that in all selected RCTs,
treatment effect was measured precisely. We assessed in 20/22 cohort studies, exposure was
accurately measured to minimise bias. As illustrated in Figs 2–5, only a proportion of individu-
als included as the ‘whole cohort’ at baseline had follow up DST as per criteria detailed in S1
Table. These criteria ranged from being performed at a regular monthly interval in all culture
positive isolates; to those who were smear/culture positive at 2 and 5–6 months; to being only
performed in cases of suspected failure/relapse. In some cases, this may have compromised
accuracy of measurement of outcome.
Risk factors associated with ADR
Figs 2–5 summarise significant associations and trends for ADR. S4 Table details all covariates
that were examined as potential risk factors.
Studies varied considerably in the potential risk factors examined. The disease burden and
pathogen factors most frequently examined were baseline mono and polyresistance (16/32),
smear positivity (8/32) and cavitatory disease (7/32). Host immune factors most frequently
examined were HIV co-infection (10/32) and CD4 lymphocyte count in HIV-infected patients
(8/32). The most frequent sociodemographic covariate examined was age (11/32). The most
frequently examined programmatic factor was self-administered therapy (SAT) versus directly
observed therapy (DOT) (8/32).
Disease burden and pathogen factors. Baseline drug resistance was positively associated
with ADR in 15/16 studies that examined its association. In our meta-analysis of 15 studies
(including 45,919 patients), baseline drug resistance (monoresistance or polyresistance) was
found to be a significant risk factor for ADR (RR 4.85, 95% CI 3.26 to 7.23), when compared
Acquired Rifamycin/Isoniazid Resistance
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Fig 1. Summary of literature search and study selection.
doi:10.1371/journal.pone.0139017.g001
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Table 1. Characteristics of included studies including HIV co-infection, proportion receiving retreatment, treatment regimen, whether treatment
was self-administered or directly observed and use of genotyping.
Reference Study location and
year
HIV
prevalence
Retreatment
(ReRx)
Regimen DOT Genotyping
carried out in a
proportion of
available
isolates
RCTs
Algerian Working
Group/British MRC
1991 Tubercle [16]
Algeria Oct
1981-Dec1983
0% Not speciﬁed IP: Regimen 1) 2(HRSZ7)
Regimen 2) 2(HREZ7) CP:
Regimen 1) 4(HR7)
Regimen 2) 2(HR7)4(H7)
DOT in IP (whilst on
streptomycin)
No
Hong Kong TB
Research Centre
Madras/BMRC Am
Rev Resp Disease
1991 [12]
Hong Kong Dec
1980- Dec 1985
Not speciﬁed Not speciﬁed Regimen 1) 6(RHSZ)
Regimen 2) 8(RHSZ)3 (E
was added for ﬁrst 3
months if retreatment
patient)
100% No
Lienhardt JAMA
2011 [17]
Algeria, Colombia,
Guinea, Vietnam,
Peru,Mozambique,
Tanzania, Bolivia
2003–2008
6.6% 0% IP: Regimen 1) 2(RHEZ7)
as FDC Regimen 2) 2
(RHEZ7) as single drugs
CP: 4(RH3)
100% Yes Spoligo and
MIRU-VNTR
Swaminathan
AJRCCM 2010 [10]
Chenai, India Feb
'01- Sep '05
100% 0% IP: Regimen 1) 2(RHEZ3)
Regimen 2) 2(RHEZ3) CP:
Regimen 1) 4(RH3)
Regimen 2) 7(RH3)
DOT was given
during IP. 1/3 doses
was given as DOT
during CP
Yes IS6110,
MIRU-VNTR,
Spoligo
TB Research Centre
IJTLD 1997 [18]
Chennai not speciﬁed Not speciﬁed Not speciﬁed IP: Regimen 1) 2(HREZ7)
Regimen 2) 2(HREZ2)
Regimen 3) 2(HRZ2)CP:
Regimen 1) 6(HE7)
Regimen 2) 4(HRE2)
Regimen 3) 4(HR2)
Regimen 1 was fully
unsupervised.
Regimen 2 and 3
were either fully or
partially supervised.
No
Vernon Lancet 1999
[8]
USA Apr 1995- early
1997
100% 47.5% IP: 2(RHEZ7/3/2) CP:
Regimen 1) 4(rifapentine/
H1) Regimen 2) 4(RH2)
100% Yes IS6110
Prospective cohorts
Aung, IJTLD 2012
[19] *operational
study with
randomisation
Bangladesh Jan '06-
Jun '07
Not speciﬁed 0% IP: 2(3) RHEZ7 CP: 4(HR3) 100% Yes Sequencing
of core region of
rpoB gene
Burman AJRCCM
2006 [9]
New York City, USA
Dec 1998- Mar 2002
100% Not speciﬁed IP: First 2 weeks: (RHEZ7)
Next 6 weeks: (RHEZ5) or
(RHEZ3) or (RHEZ2) (78%
received rifampin in IP) CP:
4-7(RH2) R = rifabutin
100% Yes Sequencing
of core region of
rpoB gene
Cox, Clin Infect Dis
2007 [20]
Karakalpakstan,
Uzbekistan and
Dashoguz,
Turkmenistan Jul
2001- Mar 2002
Not speciﬁed 45% IP: New 2(HREZ7) ReRx 2
(SRHEZ7),1(RHEZ7) CP:
New: 4(HR3) ReRx:5(HRE3)
DOT during IP Yes RFLP of
IS6110 and
spoligo
El Sahly, J of Infect,
2006 [21]
Houston, USA 1995–
2001
18.1% 6.3% *Not speciﬁed Not speciﬁed Yes RFLP of
IS6110 and
spoligo
Murray SAMJ 2000
[22]
Goldmines in
Gauteng, South
Africa, 1995
49% 27% IP: 2RHZE CP: 4RH DOT if smear+ No
(Continued)
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Table 1. (Continued)
Reference Study location and
year
HIV
prevalence
Retreatment
(ReRx)
Regimen DOT Genotyping
carried out in a
proportion of
available
isolates
Nettles, Clin Infect
Dis 2004 [23]
Baltimore, USA Jan
'93- Dec '01
27% Not speciﬁed IP: 2wks (RHEZ7) 6wks
(RHEZ2) Rifampicin or
rifabutin CP: (RHEZ2)
Rifampicin or rifabutin,
duration individualised
100% Yes RFLP of
IS6110
Pasipanodya, J Inf
Dis 2013 [24]
Western Cape, South
Africa
10% 64% IP: New 2(HREZ7) ReRx 2
(SRHEZ7),1(RHEZ7) CP:
New: 4(HR3) ReRx:5(HRE3)
DOT during IP No
Temple Clin Infect
Dis 2008 [14]
Kampala, Uganda Jul
2003- Nov 2006
48% 100% IP: 1(SRHEZ7) 2(RHEZ7)
CP: 5(RHE7)
DOT in IP
(hospitalised)
Yes RFLP of
IS6110
Retrospective
cohorts
Chien, JAC 2013 [25] Taiwan 2005 to 2011 0% Not speciﬁed WHO recommendations IP:
New 2(HREZ7) ReRx 2
(SRHEZ7),1(RHEZ7) CP:
New 4(HR3) ReRx 5(HRE3)
57% received
DOTS
No
Driver, Clin Infect
Dis, 2001 [26]
New York City Jan
1993- Jun 1996
33%,
(unknown
36%)
0% IP: Regimen 1) Regimen 2
(RHZ7) Regimen 2) 2
(RHZ7) Regimen 3) IP
with < 8weeks of Z CP:
Regimen 1) 4(RH7)
Regimen 2) 6(HE7)
Regimen 3) 7(RH7)
DOT median 21
weeks
Yes RFLP of
IS6110
Gelmanova, Bull
WHO, 2007 [27]
Tomsk, Siberia Jan
2001- Dec2001
1% Not speciﬁed WHO recommendations IP:
New) 2(HREZ7) ReRx): 2
(SRHEZ7),1(RHEZ7) CP:
New: 4(HR3) ReRx:5(HRE3)
DOT in inpatient,
outpatient and
home care setting.
Small proportion
self-administered
therapy
No
Jasmer, AJRCCM,
2004 [28]
San Francisco,
United States 1998 to
2000
13% 9% *Not speciﬁed DOT (n = 149) and
SAT (n = 223)
No
Kim BMC ID 2008
[13]
Seoul, Korea Jul
2001-Jun 2005.
36% Not speciﬁed IP: 2(RHEZ7) CP: 33% 4
(REZ7) 54% 10(RE7) 13% 7
(RE7)
Not speciﬁed No
Li CID 2005 [29] New York City Jan
1997 –Dec 2000
Not speciﬁed 28% IP: Variable rifampin or
rifabutin-based regimen,
daily or intermittent dose (2/
wk or 3/wk) for 2 months
CP: rifampin or rifabutin
regimen given x2 or 3/wk
for 4–6, 7–10 or >10
months
Not speciﬁed Yes RFLP of
IS6110 and
spoligo
Matthys, PLoS ONE,
2009 [11]
Mariinsk, Siberia,
Russia 1997 to 1998
None at entry
into prison
65% IP: 2(SRHEZ7),1(RHEZ7)
CP: 5(RHE7)
100% Yes RFLP of
IS6110
Moulding IJTLD 2004
[30]
Los Angeles, US Jun
1985-Jul 1992
Cohort known
or presumed
to be HIV
negative
Not speciﬁed IP: HR and Z or E or ZE
(duration and frequency not
speciﬁed) CP: HR (duration
and frequency not
speciﬁed)
Not speciﬁed No
Porco CID 2012 [31] California, USA Jan
1994- Dec 2006
7.5% Not speciﬁed *Not speciﬁed 100% No
(Continued)
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with patients with baseline pan-susceptible MTB (Fig 6). There was moderate heterogeneity of
the data as evidenced by I2 58% (95% CI 26 to 76%), the same positive trend was seen in all 15
studies included.
A funnel plot for the meta-analysis of baseline drug resistance as a risk factor for ADR (Fig
7) showed a dearth of smaller studies reporting negative effects. However, the asymmetry of
the funnel plot also appears to be related to substantial heterogeneity among the larger studies
Table 1. (Continued)
Reference Study location and
year
HIV
prevalence
Retreatment
(ReRx)
Regimen DOT Genotyping
carried out in a
proportion of
available
isolates
Quy IJTLD 2003 [32] Ho Chi Minh City,
Vietnam Aug 1996-
Jul 1998
Not speciﬁed 0% IP: New: 2(SHRZ7) ReRx 2
(SRHEZ7),1(RHEZ7) CP:
New: 6(HE7) ReRx:5(HRE3)
100% Yes RFLP of
IS6110
Seung CID 2004 [33] Tomsk, Siberia Nov
1996- Dec 2000
Not speciﬁed 0% IP: 2(HREZ7) In some
cases S was given instead
of E CP: 4(HR7)
DOT programme
IP- hospitalised CP-
outpatient
No
Spellman 1988 AIDS
[34]
Miami and New York,
USA Jan '88- Dec '95
12.8 5.2% *Not speciﬁed 100% No
Weis, NEJM 1994
[35] #Although
presented under
cohort studies, this
may also be
classiﬁed as an
ecological study
United States 1980 to
1992
58 amongst
485 those
tested from
1987 (12%)
Not speciﬁed IP: 1980 to 1986 included
HRE. 1986 to 1992
included HRZ +/- E or
injectable CP: Not speciﬁed
Until 1986 not DOT,
from 1986 90.5%
received DOT
No
Yoshiyama IJTLD
2004 [15]
Chiang Rai, Thailand
May 1996- Dec 2000
31% 100% of re-
registered
cohort
IP: 2(SRHEZ7),1(RHEZ7)
CP: 5(RHE7)
DOT introduced in
1996
Yes RFLP of
IS6110
Yuen, PLoSONE
2013 [36]
United States 2004 to
2011
Positive 7%
Negative
67.5%
Unknown
25.5%
0% *Not speciﬁed DOT only 61%,
DOT + SAT 37%,
SAT only 2%
No
Case controls
Bradford Lancet
1996 [37]
San Fransciso, USA
Jan '85-Dec '94
Cases 79%
Controls 27%
Cases 14%
Controls 14%
*Not speciﬁed Not speciﬁed Yes RFLP of
IS6110
Munsiff, Clin Infect
Dis 1997 [38]
New York City, USA
93–94
100% Not speciﬁed IP: Regimen contained RHZ
(+/-E), dosing regimen not
speciﬁed CP: *Not
speciﬁed
Cases: 24%
received DOT
Controls: 31%
received DOT
No
Weiner CID 2005
[39]
New York City Dec
1998- Mar 2002
100% Not speciﬁed IP: First 2 weeks: (RHEZ7)
Next 6 weeks: (RHEZ5) or
(RHEZ3) or (RHEZ2) CP: 9
(RH2)
100% Yes Sequencing
of core region of
rpoB gene
Abbreviations: IP intensive phase CP continuation phase R rifampin H isoniazid E ethambutol Z pyrazinamide S streptomycin Rx treatment wk week DOT
directly observed therapy SAT self-administered therapy X(RHEZY) X = number of months on regimen y = number of days/week on regimen ARR
acquired rifamycin resistance Spoligo Spoligotyping MIRU-VNTR (mycobacterial interspersed repetitive unit-variable- number tandem repeat) typing RFLP
of IS6110 restriction fragment length polymorphism of the IS6110 insertion element
*individualised treatment as per Centre of Disease Control, USA guidelines http://www.cdc.gov/mmwr/pdf/rr/rr5211.pdf.
Whilst treatment regimens were not explicitly stated in 6 (19%) of studies, these all included treatment with a rifamycin during intensive phase and were of
minimum 6 months duration.
doi:10.1371/journal.pone.0139017.t001
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with small standard errors, around the summary estimate of effect, with a resulting imbalance
toward a large positive effect estimate.
ADR was significantly associated with extrapulmonary/disseminated TB in 3/5 (60%) stud-
ies; with smear positivity in 4/8 (50%) studies; and with extensive radiological disease and cavi-
tatory disease in 1/4 (25%) and 1/7 (14%) studies respectively.M. tuberculosis complex strain
was a risk factor for ADR in 2/4 (50%) studies that examined its role: 1 found increased risk
with Beijing strains and 1 withM. bovis.
Host immunity and PK variability. HIV co-infection was a risk factor for ADR in 8/10
(80%) studies that assessed it. In a meta-analysis of 8/10 studies (35,595 patients), HIV was a
significant risk factor for ADR (RR 3.02, 95% CI 1.28 to 7.11) with overall high heterogeneity I2
81% (95% CI 64 to 90%) (Fig 8). Sub-group analysis by continent for ADR showed a RR of 3.23
(95% CI 1.02 to 10.26) with HIV co-infection in 5 North American studies (heterogeneity I2
29%, 95% CI 0 to 72%) whilst there was a trend towards a negative association in 2 African
studies (RR 0.3, 95% CI 0.07 to 1.19) with heterogeneity I2 12%.
A funnel plot for the meta-analysis of HIV as risk factor of ADR indicated little risk of pub-
lication bias (Fig 9).
A low CD4 lymphocyte count at diagnosis in 5/8 studies (63%) and an AIDS diagnosis in 2/
2 studies were significant risk factors for ADR amongst HIV-infected patients. Gastrointestinal
symptoms at baseline were associated with ADR in 1/1 study and concurrent use of antifungal
azoles in 2/2 studies. PK variability was found to be a risk factor for ADR in both studies exam-
ining its role. Weiner et al found that a lower area under the curve (AUC0-24hr) and lower peak
concentration (Cmax) for rifabutin was associated with increased risk of ADR. This was in a
Fig 2. RCTS- ADR and associated risk factors.
doi:10.1371/journal.pone.0139017.g002
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sub-cohort of patients who were sampled during continuation phase therapy. There was no sig-
nificant difference in isoniazid Cmax or AUC0-24hr in cases of ADR, compared with controls.
Pasipanodya et al found that low rifampicin and isoniazid peak concentrations and AUC0-24hr
preceded ADR in 3 patients.
Sociodemographic factors. Older age [4/11(36%)], foreign birth [1/3 (33%)], ethnicity [2/
5 (40%)], unemployment [1/1], substance abuse [2/4 (50%)] and homelessness [1/3 (33%)]
were found to be risk factors for ADR in certain studies.
TB regimen and adherence. Non-adherence was assessed as a risk factor for ADR in 5/32
studies and was associated with ADR in 3/5 (60%) of studies. Directly observed therapy was a
risk factor for ADR in 1/8 (12.5%) studies that compared the practice of SAT with DOT. In
contrast, SAT was found to be a risk factor for ADR in 4/8 (50%) studies. There was no associa-
tion between DOT or SAT and ADR in 3 studies. Separate drug formulation, as opposed to
fixed dose combination (FDC), was found to be a risk factor for ADR in 1/3 (33%) of studies.
Use of rifampicin in the regimen only during intensive phase [16] and lack of ethambutol [18]
in a twice/once weekly dosing regimen were associated with cases of ADR in individual RCTs
carried out in the 1990s. In one retrospective cohort study, in a sub-analysis of HIV co-infected
patients, intermittent dosing of rifampicin during the intensive phase and use of rifampicin
instead of rifabutin was associated with ADR [29]. This was in contrast to sub-analysis of HIV-
infected patients in another study where there was no significant difference in ADR comparing
rifampicin and rifabutin-based regimens [23]. In a RCT, a once weekly rifapentine based regi-
men in continuation phase was associated with ADR in HIV co-infected individuals [9].
Fig 3. Prospective cohorts- ADR and associated risk factors.
doi:10.1371/journal.pone.0139017.g003
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Cumulative incidence of ADR. Figs 2–5 report DST data and cumulative incidence of
acquired isoniazid, rifamycin and MDR for individuals studies stratified by whole cohort,
whole cohort with follow up DST, baseline pan-susceptibility, baseline mono-resistance and
baseline poly-resistance. In 25 studies, which reported acquired MDR, when considering the
overall cohort as denominator, the weighted median incidence of acquired MDR was 0.1% (5th
to 95th percentile 0.07 to 3.2%). In 20 studies reporting acquired isoniazid resistance, when
considering the overall cohort as denominator, the weighted median incidence of acquired iso-
niazid resistance was 0.1% (5th to 95th percentile 0.1 to 0.7%). In the 27 studies reporting
acquired rifamycin resistance, when considering the overall cohort as denominator, the
weighted median incidence of acquired rifamycin resistance was 0.1% (5th to 95th percentile
0.09 to 0.7%). In patients with baseline pan-susceptibility (data available in 15 studies) the
weighted median incidence of acquired MDR was 0.2% (5th to 95th percentile 0 to 0.9%). In
those with baseline pan-susceptibility, acquired isoniazid resistance (weighted median inci-
dence 0.3%, 5th to 95th percentile 0.06 to 2.7%) did not appear to be more frequent than
acquired rifamycin resistance (weighted median incidence 0.3%, 5th to 95th percentile 0 to
0.9%). The weighted median incidence of acquired MDR in patients with baseline monoresis-
tance (data available in 12 studies) was 1% (5th to 95th percentile 0.79 to 10%). The weighted
median incidence of acquired MDR in patients with baseline polyresistance (data available in 7
studies) was 10% (5th to 95th percentile 7.1 to 15.5%). It must be noted, that the above estimates
of incidence of ADR refer only to studies included in this review and with our search strategy,
we excluded studies in which no cases of ADR occurred.
Fig 4. Retrospective cohorts- ADR and associated risk factors.
doi:10.1371/journal.pone.0139017.g004
Acquired Rifamycin/Isoniazid Resistance
PLOS ONE | DOI:10.1371/journal.pone.0139017 September 25, 2015 11 / 20
Discussion
Although acquired MDR was rare overall [weighted median frequency 0.1%], it was more fre-
quent in certain risk groups such as those with baseline mono or polyresistance. A meta-analy-
sis of 15 studies with a moderately heterogeneous data set showed a RR for ADR of 4.96 in
patients with baseline drug resistance compared with baseline pan-susceptible profiles. Studies
reporting ADR as a treatment outcome varied in geographical location, HIV co-infection,
retreatment proportions and treatment regimens administered during intensive and continua-
tion phase as summarised in Table 1 and S2 Table. Weighted pooled analysis of a highly het-
erogeneous data set showed an increased risk of ADR (RR 3.02) with HIV co-infection. The
data presented disaggregated by continent showed a significant association with HIV co-infec-
tion in 5 North American studies whilst there was a trend towards a negative association in 2
African studies. This negative association of HIV with ADR in Africa, may partly be explained
by a relatively higher proportion of HIV infected patients who develop ADR dying prior to the
detection of ADR. Advanced immunosuppression as reflected by a lower baseline CD4 lym-
phocyte count or AIDS at diagnosis was a risk factor in HIV co-infected patients. Poor adher-
ence and extrapulmonary/disseminated disease were risk factors for ADR in 60% of studies.
There was less conclusive evidence regarding the role of PK variability, strain type, DOT versus
self-administered therapy, fixed dose combinations and choice of rifamycin as risk factors.
The wide range in reported incidence of ADR may be partially explained by lack of stan-
dardization in reporting. For example, where follow up culture and DST results are missing,
either the denominator can be altered to reflect this, or the denominator remains as the original
cohort number; the assumption being that those with missing DST did not develop ADR. In
Fig 5. Case-Control studies- ADR and associated risk factors.
doi:10.1371/journal.pone.0139017.g005
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this review we have presented cumulative incidence of ADR in individual studies, for both the
whole cohort and limited to those with follow up DST data.
Baseline mono or polyresistance has previously been recognised as a significant risk factor
for ADR. Lew et al [40] carried out a meta-analysis looking at the role of initial drug resistance
on TB treatment outcomes. Of note, many studies carried out in the 1970s only used rifamycins
during a 2 month intensive phase. Lew et al found that the cumulative incidence of ADR
increased from 0.8% (95% CI 0.5 to 1%) in baseline pan-susceptible cases to 6% (95% CI 4 to
8%) in baseline monoresistant cases and 14% (95% CI 9 to 20%) in baseline polyresistant cases
[40]. A review by Menzies et al [41] found that in patients with baseline isoniazid monoresis-
tance, a longer duration of rifampicin, use of streptomycin, daily therapy initially, and treat-
ment with a greater number of effective drugs were associated with reduced risk of ADR.
Jacobsen et al reported 9% progression to MDR TB in a cohort with baseline isoniazid monore-
sistance who received 12 months of quadruple therapy [42]. In many resource limited settings,
Xpert MTB/RIF is used to test for baseline rifampicin resistance and baseline isoniazid resis-
tance will go undetected. During continuation phase, those with isoniazid monoresistance
(particularly high level) who are still culture positive, will be effectively receiving rifampicin
monotherapy. Hence, there is potential for amplification of drug resistance.
Fig 6. Forest plot of comparison: 1) baseline drug resistance vs pansusceptible MTB, outcome of ADR: 1.2) ADR by region. * 1 study was excluded
as we were unable to obtain the exact proportion of patients in the study with non-MDR baseline drug resistance and baseline pan-susceptibility either from
the paper or by contacting the authors. The endpoint used for the plot for 12 studies was acquisition of isoniazid/rifamycin/multidrug resistance
[3,9,11,13,14,17,19,21,30,31,32,33] and the end point for 3 studies was acquisition of rifamycin resistance [8,28,35], based on data available.
doi:10.1371/journal.pone.0139017.g006
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The role of HIV co-infection in the acquisition of TB drug resistance has been a topic of
debate. In an immunocompromised host, there is an increased risk of disseminated TB; the lat-
ter being an independent risk factor for ADR. Hence, there may be an increased bacterial bur-
den leading to an increased probability of bacteria undergoing spontaneous mutation. It is also
hypothesized that less fit drug resistant strains survive longer in the context of poor immunity,
allowing for development of compensatory mutations to restore fitness [43–45]. Some MTB
strain types are particularly prevalent in immunocompromised hosts [45]. HIV co-infection
may cause changes in gut permeability leading to malabsorption of antituberculous drugs
[5,46]. As antiretroviral therapy (ART) becomes increasingly available and guidelines advocate
early commencement of ART, it remains to be seen if HIV co-infection will continue to be
associated with ADR.
In vitro work in hollow fibre models has suggested that PK variability and inadequate dosing
of TB drugs may be an important risk factor for ADR [47,48]. This is supported by findings
from cohort studies [24,39]. However, these results need to be confirmed in studies with robust
determination of PK indices and appropriate controls. Pasipanodya et al [49] reviewed the role
of N-acetyl-transferase type 2 genotype in acquired isoniazid resistance. The link they found
between slow acetylator status and ADR may be less significant in the context of currently uti-
lised rifampicin-containing multidrug regimens.
Fig 7. Funnel plot of studies included in meta-analysis of baseline drug resistance and ADR.
doi:10.1371/journal.pone.0139017.g007
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Two studies showed an association with MTB strain. Cox et al found an association between
Beijing strain and ADR [20]. In a database of 3696 MTB complex strains, 72% of which were
Euro-American lineage, onlyM. bovis was associated with ADR [36]. Luria-Delbrück fluctua-
tion analyses have suggested that MTB lineage 2 (Beijing) strains are associated with increased
mutation rates and acquisition of drug resistance [50]. This may potentially be through sign
epistasis where there is favourable interaction between drug resistance mutations and genetic
background of the strain [51].
There is no standardized means of measuring adherence and the measure chosen depends
on the setting, burden of disease, infrastructure and resources available. Whilst some studies
have used DOT (as opposed to SAT), as a surrogate measure of adherence, we have not made
this assumption as the outcome of DOT may be confounded by its indication. We have exam-
ined non-adherence as a separate risk factor to DOT versus SAT. Non-adherence was a signifi-
cant risk factor in 3/5 [9,36,37] of the studies that examined its association with ADR. For the 2
studies which showed no significant association between non-adherence and ADR, there was a
trend of positive association for 1 of the studies [26] but in the other, all 5 cases of ADR were
noted to be adherent with therapy. The impact of DOT versus SAT on ADR was less clear with
a protective effect of DOT seen in 50% of studies. A meta-analysis by Pasipanodya et al showed
no increased risk of microbiologic failure, relapse, or ADR with DOT compared with SAT [52].
Fig 8. Forest plot of comparison: 1) HIV status, outcome of ADR. 1.2) ADR by region.Only 8/10 studies which examined HIV as a risk factor for ADR
were included as we were unable to obtain the exact proportion of those HIV seropositive among the patients that developed ADR from either the paper or by
contacting the authors in the other 2 studies. The end point for 5 studies was acquisition of isoniazid/rifamycin/multidrug resistance [13,14,21,30,33] and the
end point for 3 studies was acquisition of rifamycin resistance [22,28,35], based on data available.
doi:10.1371/journal.pone.0139017.g008
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Intermittent dosing frequency has been linked with adverse outcomes, including ADR, when
administered during intensive phase [8,29], particularly in the context of HIV co-infection.
There are several limitations to this review. The primary focus of the review was evaluating
risk factors for ADR. It is not possible to gather any meaningful data regarding risk factors for
an event from a study in which no events are reported and consequently, studies that either
reported ADR but no risk factors or 0% ADR were excluded and this potentially affected the
estimates of ADR cumulative incidence, which was a secondary analysis. There was incomplete
MTB strain genotyping to rule out the possibility of dual mixed infection or exogenous re-
infection. Only 47% of studies confirmed ADR with identical MTB genotype at baseline and
follow-up. Even where genotyping was part of the study design, in some, a proportion of sus-
pected ADR isolates were not available for genotyping [9,14,25,28]. Many studies were retro-
spective and had small sample sizes and missing DST. Hence, some studies were likely to have
been underpowered and there may have been misclassification bias. There were no statistical
analyses of risk factors for ADR in 13 studies because the primary outcome was not ADR. We
were limited to noting trends of risk for ADR in the studies. We only conducted meta-analyses
of HIV co-infection and baseline drug resistance as risk factors. For the meta-analyses under-
taken, the weighted estimates of effect size, must be taken in context of moderate to high het-
erogeneity in the random effects model [53,54]. This heterogeneity is not surprising,
considering different geographical populations, varying MTB strains, different regimens and
Fig 9. Funnel plot of studies included in meta-analysis of HIV and ADR.
doi:10.1371/journal.pone.0139017.g009
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dosing frequencies, different programmatic factors such as self-administered vs DOT and dif-
ferent proportions of retreatment vs new patients. There were also differences in study meth-
odology such as choice of denominator in the calculation of cumulative incidence of ADR and
lack of confirmatory genotyping in all studies.
Previous reviews have focussed on a specific risk factor such as fixed dose combination vs.
separate drug formulation [55], duration and dosing frequency of rifamycin [56] and baseline
isoniazid monoresistance[40]. The strength of this review is that it consolidates the multifacto-
rial aetiology of ADR within a single systematic review.
In conclusion, baseline drug resistance and HIV co-infection were significant risk factors
for ADR. Overall, there were limitations of the current evidence and difficulties in evaluating
possible contributors to ADR with heterogeneity secondary to both clinical and/or methodo-
logical diversity. Although the data are variable, disseminated disease and non-adherence had
positive trends of association for ADR. There are likely many other variables contributing to
acquired rifamycin and/or isoniazid resistance and studies to date have not adequately evalu-
ated factors such as PK variability and MTB strain type as risk factors for ADR. The multifacto-
rial aetiology ADR in a programmatic setting should be further evaluated via appropriately
designed studies.
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